Zymeworks Inc (NASDAQ:ZYME) has received an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $19.00 for the company and are forecasting that the company will post ($0.62) EPS for the current quarter, according to Zacks. Zacks has also given Zymeworks an industry rank of 125 out of 265 based on the ratings given to related companies.

ZYME has been the subject of several recent research reports. Citigroup Inc. initiated coverage on Zymeworks in a report on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price objective for the company. Barclays PLC initiated coverage on Zymeworks in a report on Tuesday, May 23rd. They set an “overweight” rating and a $20.00 price objective for the company. Wells Fargo & Company initiated coverage on Zymeworks in a report on Tuesday, May 23rd. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Canaccord Genuity initiated coverage on Zymeworks in a report on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price objective for the company.

Shares of Zymeworks (ZYME) traded down 0.94% during midday trading on Tuesday, reaching $8.39. The company’s stock had a trading volume of 16,816 shares. Zymeworks has a 52 week low of $7.24 and a 52 week high of $14.25. The stock has a 50-day moving average price of $10.80 and a 200 day moving average price of $11.26. The stock’s market capitalization is $209.25 million.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Monday, May 15th. The company reported ($1.13) earnings per share (EPS) for the quarter. Zymeworks had a negative return on equity of 798,487.60% and a negative net margin of 6,924.35%. The firm had revenue of $0.23 million for the quarter. Equities analysts forecast that Zymeworks will post ($2.75) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/11/brokerages-set-19-00-target-price-for-zymeworks-inc-nasdaqzyme.html.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.